More Satisfied, But Why? A Pooled Patient‐level Analysis Of Treatment Satisfaction Following The Initiation Of Insulin Glargine Vs. Comparators In Insulin‐naïve Patients With Type 2 Diabetes Mellitus by W. Polonsky, L. Traylor, W. Wei, R. Shi, B. Ameer, A. Vlajnic, A. Nicolucci

10.1016/J.JDIACOMP.2006.02.004

Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers.

S. Nakar (2007)

RECOMMANDATIONS 2012 EN DIABÉTOLOGIE: Prise en charge de l'hyperglycémie dans le diabète de type 2: une approche centrée sur le patient

A. Scheen (2012)

10.4324/9781315077369-16

Diabetes Treatment Satisfaction Questionnaire: (DTSQ)

C. Bradley (2013)

10.1007/s00125-012-2534-0

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

S. Inzucchi (2012)

10.1016/J.DIABRES.2007.03.021

Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study.

R. Houlden (2007)

10.2337/DIACARE.29.04.06.DC05-0053

Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.

M. Peyrot (2005)

10.1111/j.1463-1326.2008.00871.x

Improving treatment satisfaction and other patient‐reported outcomes in people with type 2 diabetes: the role of once‐daily insulin glargine

C. Bradley (2008)

10.2478/afmnai-2014-0024

Quality of Life in Type 2 Diabetic Patients

A. Spasić (1999)

10.1111/j.1742-1241.2008.01742.x

Primary care physician beliefs about insulin initiation in patients with type 2 diabetes

R. Hayes (2008)

10.2337/DIACARE.28.10.2543

Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem.

W. Polonsky (2005)

10.1016/S0084-3741(08)79214-X

Initiate Insulin by Aggressive Titration and Education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups

J. Leahy (2008)

10.1185/03007995.2011.573623

Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population

William H. Polonsky (2011)

10.1111/j.1464-5491.2011.03329.x

Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health‐related quality of life. A prospective cohort study in primary care

T. Hajós (2011)

10.2337/DIACARE.22.3.530

Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur.

C. Bradley (1999)

10.2337/diacare.21.6.919

Well-Being and Symptoms in Relation to Insulin Therapy in Type 2 Diabetes

J. J. J. D. Sonnaville (1998)

10.1056/NEJMoa0806470

10-year follow-up of intensive glucose control in type 2 diabetes.

R. Holman (2008)

10.1185/030079906X115757

Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes

C. Currie (2006)

10.4324/9781315077369

Handbook of Psychology and Diabetes : A Guide to Psychological Measurement in Diabetes Research and Practice

C. Bradley (1994)

10.1016/S0140-6736(98)07019-6

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

UK Prospective Diabetes Study Group (1998)

10.1016/S0168-8227(00)00245-X

Effect of insulin therapy on quality of life in Type 2 diabetes mellitus: The Fremantle Diabetes Study.

T. Davis (2001)

10.2337/DIACARE.28.2.254

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.

H. Janka (2005)

10.3109/00016485509120666

The study group.

G. H. Duvel (1980)

10.2337/dc10-1926

Effect of Intensive Glycemic Lowering on Health-Related Quality of Life in Type 2 Diabetes

R. Anderson (2011)

10.2337/DIACARE.26.11.3080

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

M. Riddle (2003)

10.1016/j.diabres.2011.10.020

Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study.

S. Shah (2011)

Study (UKPDS) Group

UK Prospective Diabete (1998)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

R. Turner (1998)

10.1186/1477-7525-8-113

Barriers towards insulin therapy in type 2 diabetic patients: results of an observational longitudinal study

N. Hermanns (2010)

10.1016/J.DIABRES.2006.11.002

Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study.

S. Chatterjee (2007)

10.1186/1477-7525-5-57

The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ

C. Bradley (2007)

10.1185/030079904X5526

The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study*

J. S. Fischer (2004)

Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

MC Riddle (2003)

10.1016/S1098-3597(09)60006-5

Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus.

D. Marrero (2007)

10.1016/j.diabres.2010.04.002

Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: results from the durable trial.

L. J. Lee (2010)